Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

about

Caregiver Burden in End-Stage Ovarian Cancer.

P2860

Q37201274-6BB22F36-BBEB-45C2-97D6-8F58A6A25A3A

P2860

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

Item

http://www.wikidata.org/entity/Q43883988

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@en

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@nl

type

Item

label

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@en

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@nl

prefLabel

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@en

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@nl

P1476

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

@en

P2093

Maurie Markman

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

Second-line treatment of ovarian cancer.

A phase 3 trial of bevacizumab in ovarian cancer.

Detecting an overall survival benefit that is derived from progression-free survival

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

P2888

s11912-013-0338-0

P304

433-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-013-0338-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23933889

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

about

P2860

P2860

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921